- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Book
- October 2019
- 153 Pages
- Book
- February 2014
- 400 Pages
- Book
- May 2018
- 560 Pages
- Book
- June 2022
- 336 Pages
- Book
- March 2022
- 896 Pages
- Book
- January 2022
- 336 Pages
- Book
- December 2020
- 432 Pages
- Book
- September 2020
- 608 Pages
- Book
- September 2020
- 528 Pages
- Book
- September 2020
- 1136 Pages
- Book
- September 2024
- 304 Pages
- Book
- April 2018
- 384 Pages
- Book
- January 2018
- 904 Pages
- Book
- April 2015
- 264 Pages
- Book
- January 2012
- 424 Pages
- Book
- January 2013
- 420 Pages

The Human Diseases market is a subset of the Biology and Life Sciences industry that focuses on the diagnosis, treatment, and prevention of diseases in humans. It includes research and development of drugs, medical devices, and diagnostics, as well as the delivery of healthcare services. This market is driven by advances in medical technology, the emergence of new diseases, and the need for better treatments. It is also influenced by the availability of healthcare resources, the cost of treatments, and the changing demographics of the population.
The Human Diseases market is highly competitive, with a range of players from large pharmaceutical companies to small biotechnology firms. Companies in this market include Pfizer, Merck, Novartis, Johnson & Johnson, Roche, Sanofi, AstraZeneca, GlaxoSmithKline, AbbVie, and Bristol-Myers Squibb. Show Less Read more